Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells

Meysam Abbasi1, Afsaneh Lavasanifar, Luc G Berthiaume

  • 1Department of Biomedical Engineering, Faculty of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.

Cancer
|August 18, 2010
PubMed
Abstract

Insights

Nonviral small interfering RNA (siRNA) delivery effectively down-regulates P-glycoprotein (P-gp) in multidrug-resistant cancer cells. This approach enhances chemotherapy drug uptake and efficacy in vitro.

Area of Science:

  • Biotechnology
  • Cancer Research
  • Drug Delivery

Background:

  • Chemotherapy is a primary cancer treatment, but multidrug resistance (MDR) limits its effectiveness.
  • Overexpression of drug efflux transporter proteins, like P-glycoprotein (P-gp), is a key mechanism of MDR.
  • Developing strategies to overcome P-gp-mediated MDR is crucial for improving cancer therapy outcomes.

Purpose of the Study:

  • To investigate the feasibility of using nonviral small interfering RNA (siRNA) delivery to down-regulate P-gp.
  • To enhance the accumulation of chemotherapeutic agents in drug-resistant cancer cells.

Main Methods:

  • Evaluation of various cationic carriers for siRNA complexation and delivery.
  • Assessment of P-gp down-regulation in MDA435/LCC6 cell lines (wild type and MDR1).
  • Quantification of cellular uptake of doxorubicin and paclitaxel.

Main Results:

  • Palmitic-acid substituted poly(L-lysine) demonstrated efficient siRNA delivery into tumor cells.
  • Successful P-gp suppression of 40%-50% was achieved in MDR1 cells.
  • A 3-fold increase in doxorubicin uptake and enhanced cytotoxicity were observed in MDR1 cells.

Conclusions:

  • Nonviral siRNA delivery is an effective strategy for reducing P-gp expression on cancer cell surfaces.
  • This method can significantly enhance the efficacy of chemotherapeutic agents in vitro.
  • siRNA delivery offers a promising approach to combatting P-gp-mediated multidrug resistance in cancer.

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...